- Valuation
- ₹34,950 Cr
- 1-year change
- +100%
About NFIL
NFIL is a publicly listed company based in Mumbai (India) founded in 1967. Fluorinated compounds are synthesized and manufactured customly for various industries. The company has 2,670 employees. Its website nfil.in draws about 10 thousand monthly visits. Its Indian entity Navin Fluorine International Limited reported revenue of βΉ3,379 Cr. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Medicinal Chemistry.
Company details
Navin Fluorine International Limited (NFIL) is a CRAMS company engaged in the research and synthesis of fluorinated compounds for the pharmaceutical, agrochemical and speciality chemical industries. The companys service portfolio includes basic research, library syntheses, process development, scale-up and small and large batch manufacturing. The company has a portfolio of over 27000 compounds and over 3000 IP protected compounds through Manchester Organics, its UK subsidiary. NFILs custom synthesis services are offered mainly through its UK subsidiary Manchester Organics. The company claims to have experience in developing fluoro similars and various fluorochemical analogues of lead compounds and libraries. They offer custom synthesis and contract research services through both FFS and FTE arrangements. NFIL has a cGMP manufacturing facility in India, to cater to mg - ton scale requirements.
Recognitions & Rankings of NFIL
- Market Cap₹50,365 Cr
NAVINFLUOR · NSE
- Share Price₹10,278.00
+4.72% today
- Revenue₹3,314 Cr
FY 2025-26 · +41.1% YoY
- EBITDA₹1,075 Cr
Margin 32.4%
- Net Profit₹648 Cr
FY 2025-26 · +148.9% YoY
- P/E (TTM)55.4x
P/B 11.4x
- ROE20.1%
ROCE 20.4%
- Debt / Equity0.41
Interest cover 12.7x
- Employee Count2,670
Associated legal entities of NFIL
NFIL is associated with 2 registered companies on The Company Check; the primary company is Navin Fluorine International Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Navin Fluorine International Limited Listed CIN L24110MH1998PLC115499 | Active | 25 Jun 1998 | Mumbai, Maharashtra | ₹3,379 Cr | 1,077 | 16 | View details |
| Navin Fluorine Advanced Sciences Limited CIN U24297MH2020PLC337262 | Active | 06 Feb 2020 | Mumbai, Maharashtra | ₹842 Cr | 528 | 8 | View details |
Board of directors of Navin Fluorine International Limited (NFIL)
Navin Fluorine International Limited is the primary company behind NFIL. The boards of the 2 registered companies of NFIL currently have 14 directors; the longest-serving is Sunil Siddharth Lalbhai, appointed in 2003. 29 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sunil Siddharth Lalbhai DIN 00045590 | Director | 03 Mar 2003 | 23 yrs 8 mo | Navin Fluorine International Limited |
| Niraj Mankad DIN 00051259 | Director | 06 Feb 2020 | 6 yrs 9 mo | Navin Fluorine Advanced Sciences Limited, Navin Fluorine International Limited |
| Ashok Sinha DIN 00070477 | Director | 28 Oct 2020 | 6 yrs | Navin Fluorine International Limited |
| Atul Kumar Srivastava DIN 00046776 | Director | 07 Oct 2021 | 5 yrs 1 mo | Navin Fluorine Advanced Sciences Limited, Navin Fluorine International Limited |
| Apurva Purohit DIN 00190097 | Director | 19 Oct 2021 | 5 yrs | Navin Fluorine International Limited |
| Akshika Raj Shah DIN 09542943 | Whole-time director | 28 Mar 2022 | 4 yrs 7 mo | Navin Fluorine Advanced Sciences Limited, Navin Fluorine International Limited |
| Vishad Padmanabh Mafatlal DIN 00011350 | Whole-time director | 01 Sep 2022 | 4 yrs 2 mo | Navin Fluorine Advanced Sciences Limited, Navin Fluorine International Limited |
| Sujal Anil Shah DIN 00058019 | Director | 14 Dec 2022 | 3 yrs 11 mo | Navin Fluorine Advanced Sciences Limited, Navin Fluorine International Limited |
| Anish Pravinkumar Ganatra DIN 10074681 | Whole-time director | 18 Mar 2023 | 3 yrs 8 mo | Navin Fluorine Advanced Sciences Limited, Navin Fluorine International Limited |
| Sudhir Ramchandra Deo DIN 01122338 | Director | 28 Sep 2023 | 3 yrs 1 mo | Navin Fluorine International Limited |
| Pradip Narotam Kapadia DIN 00078673 | Director | 30 Oct 2023 | 3 yrs | Navin Fluorine Advanced Sciences Limited |
| Abhijit Jagdish Joshi DIN 07115673 | Director | 07 May 2024 | 2 yrs 6 mo | Navin Fluorine International Limited |
| Nitin Ganpati Kulkarni DIN 03042587 | Managing Director | 24 Jun 2024 | 2 yrs 4 mo | Navin Fluorine Advanced Sciences Limited, Navin Fluorine International Limited |
| Kartikeya Dube DIN 00929373 | Director | 03 Dec 2025 | 11 mo | Navin Fluorine International Limited |
People of NFIL
59 people are tracked at NFIL (28 in leadership, 31 in team); the tracked headcount is 2,670.
| Name | Role | Group |
|---|---|---|
Debabrata Bhowmik | President- Technology &design | Leadership |
Dhruvajyoti Chakraborty | BU HR Head. | Leadership |
Gyanchand Jain | President of Strategic Initiatives | Leadership |
| President of Legal and Company secretary | Leadership | |
P.S. Haridas | President of Supply Chain Management | Leadership |
Ambuj Mishra | Senior Director- Technical Business Head- Performance Materials | Leadership |
| CFO | Leadership | |
Manish Kabra | Head - Fp&a And Controller | Leadership |
Janakiraman Rajaraman | Chief Supply Chain Officer | Leadership |
Radheshyam Singh | President of Operations | Leadership |
Rajendra Sahu | President of Operations | Leadership |
Partha Roychowdhury | CEO, HPP Business | Leadership |
Jatin Swadas | Deputy General Manager Procurement | Leadership |
Sadvik Badam | Director Finance | Leadership |
Debargha Sarkar | Associate Director- Sales And Business Development | Leadership |
Amol D More | General Manager Human Resources | Leadership |
Sheetal Shetty | Head (Associate Director) - Talent Acquisition | Leadership |
Ranjeet Singh | President And Chief Commercial Office-high Performance Products Business | Leadership |
Rohit Ranjan | Associate Director- HR & TQM | Leadership |
Sonu Singh | Director - Technology & Design | Leadership |
39 more people are available in the full profile.
Complete people profiles for NFIL
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of NFIL
NFIL is a publicly listed company on the NSE with ticker symbol NAVINFLUOR in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Jun 2007
- Listed onNSE: NAVINFLUOR
- Listed entityNavin Fluorine International Limited
- Exchange sectorProcess industries
- ISININE048G01026
- Share price₹8,532.00 (+0.76% on the day) · 2026-10-14
- Market capitalisation₹43,440 Cr
- Price to earnings55.4
- EPS (diluted, trailing year)₹153.97
- Dividend yield0.18%
- Volume (last session)31,026
Financials of NFIL
Exchange-reported figures of Navin Fluorine International Limited, the listed company behind NFIL (NSE: NAVINFLUOR).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 3,314 | 2,349 | 2,065 | 2,077 | 1,453 | 1,179 | 1,062 |
| Revenue growth | +41.1% | +13.8% | -0.6% | +42.9% | +23.2% | +11.1% | - |
| EBITDA | 1,075 | 534 | 398 | 550 | 355 | 309 | 263 |
| EBITDA margin | +32.4% | +22.7% | +19.3% | +26.5% | +24.4% | +26.2% | +24.8% |
| Profit before tax | 873 | 380 | 336 | 496 | 344 | 358 | 258 |
| Net profit | 648 | 260 | 233 | 367 | 264 | 246 | 406 |
| Net profit margin | +19.6% | +11.1% | +11.3% | +17.7% | +18.1% | +20.8% | +38.2% |
| EPS (βΉ) | 129.47 | 58.18 | 54.59 | 75.72 | 53.09 | 52.02 | 82.58 |
| Balance sheet | |||||||
| Total assets | 5,474 | 4,240 | 3,854 | 3,074 | 1,992 | 1,684 | 1,453 |
| Net worth | 3,975 | 2,626 | 2,383 | 2,185 | 1,844 | 1,634 | 1,412 |
| Total debt | 1,272 | 1,466 | 1,368 | 861 | 121 | 25.06 | 1.40 |
| Cash & bank | 96.87 | 40.52 | 27.54 | 34.81 | 95.83 | 544 | 278 |
| Net working capital | 793 | 602 | 609 | 933 | 542 | 918 | 534 |
| Cash flow | |||||||
| Cash from operations | 894 | 571 | 750 | (63.59) | 74.76 | 237 | 157 |
| Cash from investing | (1,235) | (511) | (1,094) | (656) | (172) | (237) | 85.14 |
| Cash from financing | 344 | (46.70) | 336 | 658 | 41.50 | (45.05) | (80.92) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,045 | 938 | 892 | 758 | 725 | 701 | 606 | 519 |
| Revenue growth (YoY) | +44.1% | +33.8% | +47.2% | +46.3% | +38.5% | - | - | - |
| Other income | 35.09 | 31.31 | 15.58 | 18.21 | 13.91 | 11.83 | 10.48 | 11.16 |
| EBITDA | 357 | 321 | 287 | 246 | 207 | 179 | 147 | 107 |
| EBITDA margin | +34.2% | +34.2% | +32.2% | +32.5% | +28.5% | +25.5% | +24.3% | +20.7% |
| Depreciation | 41.68 | 41.22 | 36.16 | 36.58 | 35.24 | 35.26 | 29.56 | 27.90 |
| Interest | 32.12 | 28.94 | 28.26 | 30.30 | 30.35 | 28.26 | 20.21 | 13.86 |
| Profit before tax | 318 | 282 | 238 | 198 | 155 | 127 | 108 | 76.75 |
| Tax | 75.05 | 69.68 | 52.86 | 49.13 | 37.94 | 32.04 | 24.42 | 17.93 |
| Net profit | 243 | 213 | 185 | 148 | 117 | 94.98 | 83.60 | 58.82 |
| EPS (βΉ) | 47.39 | 41.43 | 36.13 | 29.02 | 23.59 | 19.13 | 16.84 | 11.85 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,302 | 1,687 | 1,421 | 1,628 | 1,404 | 1,133 | 1,022 |
| Revenue growth | +36.5% | +18.7% | -12.7% | +16.0% | +23.9% | +10.8% | - |
| EBITDA | 657 | 339 | 236 | 422 | 355 | 311 | 261 |
| EBITDA margin | +28.5% | +20.1% | +16.6% | +25.9% | +25.3% | +27.4% | +25.5% |
| Profit before tax | 656 | 321 | 292 | 418 | 347 | 410 | 257 |
| Net profit | 472 | 214 | 195 | 304 | 267 | 251 | 397 |
| Net profit margin | +20.5% | +12.7% | +13.8% | +18.7% | +19.0% | +22.1% | +38.8% |
| EPS (βΉ) | 95.16 | 48.78 | 47.46 | 63.07 | 53.77 | 60.45 | 80.81 |
| Balance sheet | |||||||
| Total assets | 3,777 | 2,584 | 2,396 | 2,182 | 1,907 | 1,690 | 1,420 |
| Net worth | 3,666 | 2,497 | 2,302 | 2,141 | 1,864 | 1,650 | 1,389 |
| Total debt | 43.87 | 57.92 | 64.44 | 13.99 | 16.06 | 14.37 | 0.00 |
| Cash & bank | 64.87 | 6.96 | 6.43 | 13.98 | 78.17 | 389 | 258 |
| Net working capital | 451 | 336 | 529 | 788 | 798 | 760 | 506 |
| Cash flow | |||||||
| Cash from operations | 511 | 261 | 556 | 152 | 237 | 296 | 155 |
| Cash from investing | (1,129) | (183) | (517) | (157) | (181) | (345) | 76.67 |
| Cash from financing | 626 | (76.31) | (45.99) | (59.29) | (57.96) | (43.56) | (75.70) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 695 | 627 | 570 | 562 | 543 | 485 | 440 | 386 |
| Revenue growth (YoY) | +28.0% | +29.2% | +29.6% | +45.8% | +44.3% | - | - | - |
| Other income | 35.84 | 31.25 | 19.87 | 33.45 | 14.87 | 11.95 | 11.08 | 12.46 |
| Total expenses | 450 | 443 | 428 | 397 | 389 | 373 | 348 | 314 |
| EBITDA | 245 | 184 | 142 | 165 | 154 | 112 | 91.74 | 71.74 |
| EBITDA margin | +35.3% | +29.3% | +24.9% | +29.3% | +28.4% | +23.1% | +20.9% | +18.6% |
| Depreciation | 21.10 | 22.32 | 19.14 | 19.76 | 18.80 | 18.83 | 17.39 | 17.10 |
| Interest | 4.88 | 2.80 | 2.16 | 2.08 | 0.84 | 0.55 | 0.66 | 1.29 |
| Profit before tax | 255 | 190 | 141 | 177 | 149 | 104 | 84.77 | 65.81 |
| Tax | 64.20 | 54.66 | 34.72 | 42.54 | 36.67 | 27.88 | 19.53 | 15.76 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,045 | 938 | 892 | 758 | 725 | 701 | 606 | 519 |
| Revenue growth (YoY) | +44.1% | +33.8% | +47.2% | +46.3% | +38.5% | - | - | - |
| Other income | 35.09 | 31.31 | 15.58 | 18.21 | 13.91 | 11.83 | 10.48 | 11.16 |
| EBITDA | 357 | 321 | 287 | 246 | 207 | 179 | 147 | 107 |
| EBITDA margin | +34.2% | +34.2% | +32.2% | +32.5% | +28.5% | +25.5% | +24.3% | +20.7% |
| Depreciation | 41.68 | 41.22 | 36.16 | 36.58 | 35.24 | 35.26 | 29.56 | 27.90 |
| Interest | 32.12 | 28.94 | 28.26 | 30.30 | 30.35 | 28.26 | 20.21 | 13.86 |
| Profit before tax | 318 | 282 | 238 | 198 | 155 | 127 | 108 | 76.75 |
| Tax | 75.05 | 69.68 | 52.86 | 49.13 | 37.94 | 32.04 | 24.42 | 17.93 |
| Net profit | 243 | 213 | 185 | 148 | 117 | 94.98 | 83.60 | 58.82 |
| EPS (βΉ) | 47.39 | 41.43 | 36.13 | 29.02 | 23.59 | 19.13 | 16.84 | 11.85 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 3,314 | 2,349 | 2,065 | 2,077 | 1,453 | 1,179 | 1,062 |
| Revenue growth | +41.1% | +13.8% | -0.6% | +42.9% | +23.2% | +11.1% | - |
| Other income | 65.29 | 43.73 | 108 | 35.73 | 39.22 | 94.55 | 33.33 |
| Total expenses | 2,239 | 1,816 | 1,667 | 1,527 | 1,099 | 870 | 798 |
| Employee cost | 307 | 297 | 286 | 249 | 182 | 142 | 131 |
| EBITDA | 1,075 | 534 | 398 | 550 | 355 | 309 | 263 |
| EBITDA margin | +32.4% | +22.7% | +19.3% | +26.5% | +24.4% | +26.2% | +24.8% |
| Depreciation | 149 | 119 | 96.16 | 62.64 | 47.90 | 44.17 | 37.00 |
| Interest | 118 | 77.93 | 74.56 | 27.52 | 1.90 | 1.84 | 2.00 |
| Profit before tax | 873 | 380 | 336 | 496 | 344 | 358 | 258 |
| Tax | 210 | 91.49 | 65.03 | 121 | 81.15 | 111 | (144) |
| Net profit | 648 | 260 | 233 | 367 | 264 | 246 | 406 |
| Net profit margin | +19.6% | +11.1% | +11.3% | +17.7% | +18.1% | +20.8% | +38.2% |
| EPS (βΉ) | 129.47 | 58.18 | 54.59 | 75.72 | 53.09 | 52.02 | 82.58 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.25 | 9.92 | 9.91 | 9.91 | 9.91 | 9.90 | 9.90 |
| Reserves & surplus | 3,964 | 2,616 | 2,373 | 2,175 | 1,834 | 1,624 | 1,402 |
| Shareholders' funds (net worth) | 3,975 | 2,626 | 2,383 | 2,185 | 1,844 | 1,634 | 1,412 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 1,226 | 1,441 | 1,340 | 849 | 104 | 2.52 | 1.40 |
| Unsecured loans | 45.40 | 25.66 | 28.52 | 12.15 | 16.35 | 22.54 | 0.00 |
| Total debt | 1,272 | 1,466 | 1,368 | 861 | 121 | 25.06 | 1.40 |
| Total liabilities | 5,474 | 4,240 | 3,854 | 3,074 | 1,992 | 1,684 | 1,453 |
| Assets | |||||||
| Gross block | 3,898 | 3,180 | 2,203 | 1,899 | 749 | 694 | 642 |
| Net block | 3,324 | 2,736 | 1,875 | 1,646 | 556 | 540 | 529 |
| Capital work in progress | 143 | 355 | 711 | 279 | 742 | 94.87 | 38.85 |
| Investments | 1,229 | 480 | 495 | 43.81 | 118 | 99.08 | 195 |
| Inventories | 446 | 322 | 372 | 468 | 258 | 180 | 158 |
| Sundry debtors | 752 | 582 | 513 | 562 | 358 | 284 | 218 |
| Cash & bank balances | 96.87 | 40.52 | 27.54 | 34.81 | 95.83 | 544 | 278 |
| Loans & advances | 267 | 172 | 155 | 289 | 204 | 102 | 55.93 |
| Total current assets | 1,562 | 1,117 | 1,067 | 1,353 | 915 | 1,110 | 710 |
| Total current liabilities | 769 | 515 | 458 | 420 | 373 | 193 | 176 |
| Net working capital | 793 | 602 | 609 | 933 | 542 | 918 | 534 |
| Total assets | 5,474 | 4,240 | 3,854 | 3,074 | 1,992 | 1,684 | 1,453 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 19.68 | 6.64 | 14.47 | 75.74 | 132 | 177 | 15.87 |
| Net cash from operating activities | 894 | 571 | 750 | (63.59) | 74.76 | 237 | 157 |
| Net cash from investing activities | (1,235) | (511) | (1,094) | (656) | (172) | (237) | 85.14 |
| Net cash from financing activities | 344 | (46.70) | 336 | 658 | 41.50 | (45.05) | (80.92) |
| Net change in cash | 2.87 | 13.04 | (7.83) | (61.27) | (56.11) | (44.88) | 161 |
| Closing cash | 96.87 | 40.52 | 27.54 | 34.81 | 95.83 | 544 | 278 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +41.1% | +13.8% | -0.6% | +42.9% | +23.2% | +11.1% | - |
| EBITDA growth | +101.4% | +34.0% | -27.6% | +55.1% | +14.7% | +17.4% | - |
| PBT growth | +129.7% | +13.3% | -32.3% | +44.1% | -3.8% | +38.8% | +14.9% |
| Net income growth | +148.9% | +11.7% | -36.4% | +39.2% | +7.3% | -39.4% | - |
| Revenue CAGR (3Y) | +16.8% | +17.4% | +20.5% | +25.1% | +13.4% | +8.9% | +12.7% |
| EBITDA CAGR (3Y) | +25.0% | +14.6% | +8.8% | +27.8% | +17.6% | +12.9% | +18.4% |
| Profitability & leverage | |||||||
| Net income margin | +20.0% | +12.3% | +13.1% | +18.1% | +18.1% | +21.0% | +37.8% |
| Return on capital employed | +20.4% | +11.3% | +10.4% | +20.7% | +18.8% | +22.9% | +20.4% |
| Return on net worth | +20.1% | +11.5% | +10.2% | +18.6% | +15.1% | +16.2% | +32.3% |
| Debt / equity | 0.41 | 0.57 | 0.49 | 0.24 | 0.04 | 0.01 | 0.00 |
| Long-term debt / equity | 0.31 | 0.42 | 0.39 | 0.22 | 0.04 | 0.01 | 0.00 |
| Interest cover | 12.73 | 18.81 | 24.68 | 5.64 | 0.62 | 0.69 | 0.88 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.94 | 0.87 | 1.01 | 1.57 | 2.01 | 1.77 | 1.84 |
| Inventory turnover | 8.63 | 6.77 | 4.92 | 5.73 | 6.64 | 6.97 | 7.87 |
| Debtors turnover | 4.97 | 4.29 | 3.85 | 4.52 | 4.53 | 4.69 | 5.43 |
| EPS (βΉ) | 129.47 | 58.18 | 54.59 | 75.72 | 53.09 | 52.02 | 82.58 |
| Dividend per share (βΉ) | 8.60 | 7.00 | 15.00 | 12.00 | 11.00 | 11.00 | 11.00 |
| Book value per share (βΉ) | 775.53 | 529.48 | 480.86 | 440.96 | 372.19 | 330.03 | 285.42 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 695 | 627 | 570 | 562 | 543 | 485 | 440 | 386 |
| Revenue growth (YoY) | +28.0% | +29.2% | +29.6% | +45.8% | +44.3% | - | - | - |
| Other income | 35.84 | 31.25 | 19.87 | 33.45 | 14.87 | 11.95 | 11.08 | 12.46 |
| Total expenses | 450 | 443 | 428 | 397 | 389 | 373 | 348 | 314 |
| EBITDA | 245 | 184 | 142 | 165 | 154 | 112 | 91.74 | 71.74 |
| EBITDA margin | +35.3% | +29.3% | +24.9% | +29.3% | +28.4% | +23.1% | +20.9% | +18.6% |
| Depreciation | 21.10 | 22.32 | 19.14 | 19.76 | 18.80 | 18.83 | 17.39 | 17.10 |
| Interest | 4.88 | 2.80 | 2.16 | 2.08 | 0.84 | 0.55 | 0.66 | 1.29 |
| Profit before tax | 255 | 190 | 141 | 177 | 149 | 104 | 84.77 | 65.81 |
| Tax | 64.20 | 54.66 | 34.72 | 42.54 | 36.67 | 27.88 | 19.53 | 15.76 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,302 | 1,687 | 1,421 | 1,628 | 1,404 | 1,133 | 1,022 |
| Revenue growth | +36.5% | +18.7% | -12.7% | +16.0% | +23.9% | +10.8% | - |
| Other income | 87.53 | 55.54 | 120 | 41.00 | 37.47 | 141 | 31.34 |
| Total expenses | 1,645 | 1,348 | 1,185 | 1,206 | 1,048 | 822 | 762 |
| Employee cost | 221 | 218 | 210 | 203 | 153 | 116 | 117 |
| EBITDA | 657 | 339 | 236 | 422 | 355 | 311 | 261 |
| EBITDA margin | +28.5% | +20.1% | +16.6% | +25.9% | +25.3% | +27.4% | +25.5% |
| Depreciation | 80.02 | 69.88 | 57.58 | 42.60 | 44.25 | 40.67 | 33.74 |
| Interest | 7.88 | 3.19 | 4.96 | 2.05 | 1.66 | 1.42 | 1.60 |
| Profit before tax | 656 | 321 | 292 | 418 | 347 | 410 | 257 |
| Tax | 169 | 79.37 | 57.30 | 106 | 80.55 | 110 | (143) |
| Net profit | 472 | 214 | 195 | 304 | 267 | 251 | 397 |
| Net profit margin | +20.5% | +12.7% | +13.8% | +18.7% | +19.0% | +22.1% | +38.8% |
| EPS (βΉ) | 95.16 | 48.78 | 47.46 | 63.07 | 53.77 | 60.45 | 80.81 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.25 | 9.92 | 9.91 | 9.91 | 9.91 | 9.90 | 9.90 |
| Reserves & surplus | 3,656 | 2,487 | 2,292 | 2,131 | 1,854 | 1,640 | 1,379 |
| Shareholders' funds (net worth) | 3,666 | 2,497 | 2,302 | 2,141 | 1,864 | 1,650 | 1,389 |
| Secured loans | 0.10 | 34.96 | 39.65 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 43.77 | 22.96 | 24.79 | 13.99 | 16.06 | 14.37 | 0.00 |
| Total debt | 43.87 | 57.92 | 64.44 | 13.99 | 16.06 | 14.37 | 0.00 |
| Total liabilities | 3,777 | 2,584 | 2,396 | 2,182 | 1,907 | 1,690 | 1,420 |
| Assets | |||||||
| Gross block | 1,297 | 1,113 | 938 | 684 | 604 | 544 | 519 |
| Net block | 906 | 783 | 672 | 468 | 429 | 403 | 413 |
| Capital work in progress | 64.44 | 54.21 | 45.41 | 154 | 25.88 | 36.53 | 38.85 |
| Investments | 2,359 | 1,420 | 1,154 | 736 | 619 | 450 | 296 |
| Inventories | 199 | 169 | 215 | 327 | 229 | 154 | 136 |
| Sundry debtors | 600 | 442 | 320 | 393 | 352 | 276 | 209 |
| Cash & bank balances | 64.87 | 6.96 | 6.43 | 13.98 | 78.17 | 389 | 258 |
| Loans & advances | 137 | 60.42 | 285 | 258 | 338 | 101 | 56.85 |
| Total current assets | 1,002 | 678 | 827 | 991 | 998 | 921 | 660 |
| Total current liabilities | 552 | 343 | 298 | 204 | 200 | 160 | 154 |
| Net working capital | 451 | 336 | 529 | 788 | 798 | 760 | 506 |
| Total assets | 3,777 | 2,584 | 2,396 | 2,182 | 1,907 | 1,690 | 1,420 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.06 | 1.69 | 9.09 | 73.51 | 76.07 | 169 | 12.70 |
| Net cash from operating activities | 511 | 261 | 556 | 152 | 237 | 296 | 155 |
| Net cash from investing activities | (1,129) | (183) | (517) | (157) | (181) | (345) | 76.67 |
| Net cash from financing activities | 626 | (76.31) | (45.99) | (59.29) | (57.96) | (43.56) | (75.70) |
| Net change in cash | 7.46 | 1.37 | (7.40) | (64.42) | (2.56) | (93.08) | 156 |
| Closing cash | 64.87 | 6.96 | 6.43 | 13.98 | 78.17 | 389 | 258 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +36.5% | +18.7% | -12.7% | +16.0% | +23.9% | +10.8% | - |
| EBITDA growth | +93.8% | +43.9% | -44.2% | +18.7% | +14.3% | +19.2% | - |
| PBT growth | +104.3% | +9.9% | -30.1% | +20.5% | -15.3% | +59.5% | +13.3% |
| Net income growth | +121.0% | +9.5% | -35.8% | +14.0% | +6.6% | -36.9% | - |
| Revenue CAGR (3Y) | +12.2% | +6.3% | +7.8% | +16.8% | +13.7% | +9.0% | +13.7% |
| EBITDA CAGR (3Y) | +15.9% | -1.6% | -8.8% | +17.4% | +17.7% | +13.8% | +20.3% |
| Profitability & leverage | |||||||
| Net income margin | +21.2% | +14.3% | +16.6% | +19.2% | +19.0% | +26.4% | +39.1% |
| Return on capital employed | +20.9% | +13.0% | +10.6% | +20.6% | +19.4% | +22.0% | +20.7% |
| Return on net worth | +15.8% | +10.1% | +8.8% | +15.6% | +15.2% | +16.5% | +32.7% |
| Debt / equity | 0.02 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 |
| Long-term debt / equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Interest cover | 1.37 | 1.19 | 2.79 | 0.54 | 0.53 | 0.53 | 0.70 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.91 | 1.65 | 1.75 | 2.53 | 2.44 | 2.13 | 2.23 |
| Inventory turnover | 12.50 | 8.80 | 5.24 | 5.85 | 7.31 | 7.80 | 8.93 |
| Debtors turnover | 4.42 | 4.43 | 3.99 | 4.37 | 4.47 | 4.67 | 5.43 |
| EPS (βΉ) | 95.16 | 48.78 | 47.46 | 63.07 | 53.77 | 60.45 | 80.81 |
| Dividend per share (βΉ) | 8.60 | 7.00 | 15.00 | 12.00 | 11.00 | 11.00 | 11.00 |
| Book value per share (βΉ) | 715.27 | 503.50 | 464.54 | 432.09 | 376.23 | 333.31 | 280.72 |
Web traffic of NFIL
The website of NFIL (nfil.in) receives about 10.5K visits a month.
- Monthly visits10.5K
▲ 49.5% vs previous month
Websites whose visitors overlap most with NFIL. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| nesco.in | 91% | 21.7K | #1,041,485 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as NFIL (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nfil
Complete news archive for NFIL
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NFIL
NFIL was founded in 1967.
NFIL is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
NFIL has 2,670 employees.
The primary company behind NFIL, Navin Fluorine International Limited, reported revenue of βΉ3,379 Cr for FY 2026, up 41% year on year.
Navin Fluorine International Limited (NFIL) is a CRAMS company engaged in the research and synthesis of fluorinated compounds for the pharmaceutical, agrochemical and speciality chemical industries. The companys service portfolio includes basic research, library syntheses, process development, scale-up and small and large batch manufacturing. The company has a portfolio of over 27000 compounds and over 3000 IP protected compounds through Manchester Organics, its UK subsidiary. NFILs custom synthesis services are offered mainly through its UK subsidiary Manchester Organics. The company claims to have experience in developing fluoro similars and various fluorochemical analogues of lead compounds and libraries. They offer custom synthesis and contract research services through both FFS and FTE arrangements. NFIL has a cGMP manufacturing facility in India, to cater to mg - ton scale requirements.
Yes, NFIL is publicly traded on NSE under the ticker symbol NAVINFLUOR.
NFIL is associated with 2 legal entities: Navin Fluorine International Limited, Navin Fluorine Advanced Sciences Limited.
The legal entities of NFIL currently have 17 directors, including Vishad Padmanabh Mafatlal, Sujal Anil Shah, Niraj Mankad and others.

